We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Drug that Mimics Nicotine May Be Used to Treat Cognitive Disorders

By Biotechdaily staff writers
Posted on 14 May 2007
Researchers have isolated a compound that by acting on the brain cell receptors stimulated by nicotine may be a potential drug candidate for treatment of cognitive disorders such as schizophrenia, Alzheimer's disease, and attention deficit hyperactivity disorder (ADHD).

Nicotine, which mimics the affects of acetylcholine, acts primarily on the autonomic nervous system. More...
In a dose of less than 50 mg, it can cause respiratory failure and general paralysis. Smaller toxic doses can cause heart palpitations, lowered blood pressure, nausea, and dizziness. A person who smokes inhales approximately 3 mg from one cigarette. This amount increases the heart rate, constricts the blood vessels, and acts on the central nervous system, imparting a feeling of alertness and well-being. Anecdotal evidence suggests that many people with the mental illness use tobacco as a sort of self-medication to help them think more clearly.

Investigators at the University of California, Irvine (USA) searched for compounds that would stimulate nicotine receptors without nicotine's side effects (especially if the nicotine is administered by tobacco smoke).

They reported in the April 30, 2007, online edition of the Proceedings of the [U.S.] National Academy of Sciences that they had found a selective acetyl cholinesterase-positive allosteric modulator that corrected sensory-gating deficits and improved working memory in a rat model.

"We would like to see this lead to a drug that would address specifically the cognitive deficits found in schizophrenia,” said senior author Dr. Kelvin W. Gee, professor of pharmacology, at the University of California, Irvine.


Related Links:
University of California, Irvine

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
Manual Pipetting Aid
Pipette Controllers macro
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Nian Sun has spent years perfecting a device that he believes could change the way diseases are detected. (Photo courtesy of Alyssa Stone/Northeastern University)

Rapid Breath Sensor Detects SARS-CoV-2 from Exhaled Air

Nasal swabs and polymerase chain reaction (PCR) testing have been central to identifying SARS-CoV-2, but they can be uncomfortable, slow, and logistically complex when samples require transport.... Read more

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

Comprehensive Genomic Testing Expands Treatment Options for Advanced Cancers

Selecting effective therapies for advanced cancers remains difficult because standard tumor testing often targets only a limited set of genes. As options dwindle, many patients face decisions without strong... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.